Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT

Abstract

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. ⁶⁸Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several ¹⁸F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of ¹⁸F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of ¹⁸F-PSMA-1007. Results:¹⁸F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in ¹⁸F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUV_max, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 ¹⁸F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, ¹⁸F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.

Keywords: 18F-PSMA-1007; PET/CT; PSMA-PET; biochemical recurrence; peptides; prostate cancer.